Evidence map›Paper›PMID 40884302›Full record

Trial reportClinical pharmacology in drug development2026

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double-Blind, Placebo-Controlled Study.

Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye

Abstract readRandomized Controlled TrialClinical Trial, Phase I
In one paragraph

Trial report in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan WilliamsLundbeck LLC, Deerfield, IL, USA.
Rosa ChanLundbeck LLC, Deerfield, IL, USA.
Chad OrevilloLongboard Pharmaceuticals (now part of Lundbeck LLC), La Jolla, CA, USA.
Gale O'ConnellLundbeck Ltd, Watford, UK.
Dewey McLinLongboard Pharmaceuticals (now part of Lundbeck LLC), La Jolla, CA, USA.
Shikha PolegaLundbeck LLC, Deerfield, IL, USA.
Nuggehally R SrinivasLundbeck LLC, Deerfield, IL, USA.
Randall KayeLongboard Pharmaceuticals (now part of Lundbeck LLC), La Jolla, CA, USA.

Funding

Longboard PharmaceuticalsLundbeck
6 · The paper itself

Abstract

Bexicaserin (LP352) is a selective superagonist of the 5-hydroxytryptamine 2C (5-HT

Indexed as

Serotonin 5-HT2 Receptor AgonistsAdolescentAdultDose-Response Relationship, DrugDouble-Blind MethodFemaleHealthy VolunteersHumansMaleMiddle AgedProlactinYoung AdultProlactinSerotonin 5-HT2 Receptor Agonists5‐HT2Cbexicaserinepilepsymultiple ascending dosepharmacodynamicspharmacokineticsprolactin

Identifiers

PMID40884302
PMCPMC12814314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.